RDD Blog » Uncategorized

R&D Directions Insider

Archive for the ‘ Uncategorized ’ Category

‘Breakthrough’ startups reap investments from new early-stage fund

Wednesday, January 25th, 2012

Cambridge, Mass.-based Flagship Ventures recently launched the company's largest fund to date, raising $270 million for its life sciences funds, money that will add around 20 new biotechnology companies to Flagship's portfolio, according to officials. With the closing of the new fund, the company now has ...

Posted in Uncategorized, drug discovery | No Comments »

Lifecycle modeling and simulation: poised to transform drug development

Thursday, January 19th, 2012

(editor's note: this is a special guest post from Quintiles) By Michael Oâ€™Kelly, Senior Biostatistics Director, Center for Statistics in Drug Development, Innovation, Quintiles To build their 1903 flyer, the Wright Brothers modeled and tested wing shapes in a wind tunnel to reduce costs. A century later, 800,000 simulation hours on the ...

Posted in Uncategorized | No Comments »

Survey: Lack of funds, regulatory climate threaten biomedical industry

Friday, January 13th, 2012

Future growth for the biomedical industry faces growing and unprecedented threats, according to a newly released survey of CEOs from life sciences companies in California, the largest biomedical cluster in the world. The three biggest threats reported were access to capital, a burdensome and uncertain regulatory environment, and lack of ...

Posted in FDA, Uncategorized, clinical trials, drug discovery | No Comments »

Biotech startup continues hot streak

Tuesday, January 10th, 2012

If you have been following some of the buzz out of the JP Morgan Healthcare Conference this week, access to traditionalÂ venture capital remains difficult for biomedical companies, particularly for biotech startups. Thus, opportunities to forge licensing agreements or corporate partnerships with large biopharma companies has become increasingly vital for startups ...

Posted in Uncategorized, drug discovery | No Comments »

Pediatric trial education in focus

Monday, November 14th, 2011

With new legislation and regulatory polices calling for more pediatric research as part of a drug-development program, the need for increased education around pediatric clinical trials is paramount, experts in this space stress. Unlike the case under earlier regulations, companies developing a drug intended for an adult market can no ...

Posted in CRO, Uncategorized, clinical trials | No Comments »

African-American patient recruitment: Trust matters

Monday, November 7th, 2011

Inherent in effective patient recruitment for clinical trials is gaining sufficient trust from prospective subjects. Although this can be considered a universal predicate to study participation, there is a considerably greater need for this foundation when it comes to African-American patient populations, according to Carmen Gonzalez, manager of strategy and ...

Posted in Uncategorized, clinical trials | No Comments »

Smart pill quickens drug assessment process

Friday, October 28th, 2011

In case you missed the news, there was a pretty neat technology unveiling at this week's annual meeting of the American Association of Pharmaceutical Scientists, which wrapped up yesterday. New partnersÂ Bio-Images Research Ltd. and Medimetrics Personalized Drug Delivery B.V. introduced a smart pill technology called the IntelliCap, declaring it a ...

Posted in Uncategorized, clinical trials, drug discovery | No Comments »

Metabolomic profiling could benefit personalized med efforts

Monday, September 12th, 2011

The most extensive and comprehensive genome wide associating study ever conducted was recently published in Nature. The study found clear links between human genetic markers and diseases such as cancer, diabetes, cardiovascular and kidney disorders, gout, venous thromboembolism, and Crohnâ€™s disease. The topic of personalized medicine via chemical biomarkers, or metabolomics, ...

Posted in Uncategorized | No Comments »

‘Lower costs and better outcomes are mission critical’ for sponsors

Wednesday, July 27th, 2011

We reported last week that Wendel Barr, the former chief operating officer at contract research giant Covance and 11-year executive with the company, was named CEO of Synteract, a smaller privately held CRO based in San Diego. We caught up with Mr. Barr after his move across country (Covance headquarters are ...

Posted in CRO, Uncategorized | No Comments »

Covance exec takes head reins at smaller CRO

Monday, July 18th, 2011

Today, I was alerted to an interesting hire in the CRO arena, where executives jumping from one company to another is fairly common. This one, however â€“ the appointment this morning of Wendel Barr as the new CEO of San Diego-based Synteract Inc. â€“ is worth noting because of the ...

Posted in CRO, Uncategorized | 1 Comment »

©2012 UBM Canon